ALSO NOTED: Aphton files for bankruptcy; Akorn wins FDA OK; and much more...

> Philadelphia-based Aphton has filed for bankruptcy. The company is looking for offers to buy its assets. Report [1]

> Akorn shares were on the rise after reporting FDA approval of an ANDA for Orphenadrine Citrate Injection. Report [2]

> Wyeth has developed a new contraceptive from traditional therapies that eliminates a woman's monthly periods. Report [3] (WSJ sub. req.)

> Progenics announced positive results from a Phase III trial of a subcutaneous form of the investigational drug methylnaltrexone for treatment of opioid-induced constipation in cancer and cardio vascular disease patients. Report [4]

> In a clear signal of a looming drug price war, Novartis reportedly has plans to slash the cost of a range of generics in Germany and Switzerland. Report [5]

> Actelion announced that new data provides solid grounds to explore Tracleer as a therapy for idiopathic pulmonary fibrosis. Report [6]

> Wyeth has received final judicial clearance for its revised fen-phen settlement agreement. Report [7]

> Roche expects the UK to issue a license for the early use of Herceptin in breast cancer. Report [8]

> Ranbaxy says three of its AIDS drugs have been added to the WHO list of approved pharmaceuticals for developing countries. Report [9]

> Chimerix has acquired Dr. Leroy Townsend's lifetime library of chemical lead compounds from the University of Michigan. Release [10]

And Finally… A large new cancer trial sponsored by the National Cancer Institute will use genetic profiling to determine which women are likely to benefit from chemotherapy. Article [11]